Liquid Biopsy in Breast Cancer

Incorvaia, Lorena; Castiglia, Marta; Perez, Alessandro; Massihnia, Daniela; Caruso, Stefano; Altıntaş, Sevilay; Calò, Valentina; Russo, Antonio

doi:10.1007/978-3-319-55661-1_9

Cited by 3 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Circulating tumor DNA analysis may reveal the mutational landscape of metastatic disease and predict recurrence or response to therapy [44]. A retrospective study of primary breast cancer patients detected metastatic disease, including bone metastases, by measuring tumor-specific chromosomal rearrangements in ctDNA using droplet-based digital PCR technologies from plasma samples, nearly 1 year before clinical recurrence detection.…”

Section: Circulating Tumor Dnamentioning

confidence: 99%

Biopsy Techniques for Musculoskeletal Tumors: Basic Principles and Specialized Techniques

Mavrogenis,

Altsitzioglou,

Tsukamoto

et al. 2024

Current Oncology

View full text Add to dashboard Cite

Biopsy is a pivotal component in the diagnostic process of bone and soft tissue tumors. The objective is to obtain adequate tissue without compromising local tumor dissemination and the patient’s survival. This review explores contemporary principles and practices in musculoskeletal biopsies, emphasizing the critical role of diagnostic accuracy while also delving into the evolving landscape of liquid biopsies as a promising alternative in the field. A thorough literature search was done in PubMed and Google Scholar as well as in physical books in libraries to summarize the available biopsy techniques for musculoskeletal tumors, discuss the available methods, risk factors, and complications, and to emphasize the challenges related to biopsies in oncology. Research articles that studied the basic principles and specialized techniques of biopsy techniques in tumor patients were deemed eligible. Their advantages and disadvantages, technical and pathophysiological mechanisms, and possible risks and complications were reviewed, summarized, and discussed. An inadequately executed biopsy may hinder diagnosis and subsequently impact treatment outcomes. All lesions should be approached with a presumption of malignancy until proven otherwise. Liquid biopsies have emerged as a potent non-invasive tool for analyzing tumor phenotype, progression, and drug resistance and guiding treatment decisions in bone sarcomas and metastases. Despite advancements, several barriers remain in biopsies, including challenges related to costs, scalability, reproducibility, and isolation methods. It is paramount that orthopedic oncologists work together with radiologists and pathologists to enhance diagnosis, patient outcomes, and healthcare costs.

show abstract

Section: Circulating Tumor Dnamentioning

confidence: 99%

Biopsy Techniques for Musculoskeletal Tumors: Basic Principles and Specialized Techniques

Mavrogenis,

Altsitzioglou,

Tsukamoto

et al. 2024

Current Oncology

View full text Add to dashboard Cite

show abstract

“…Adopting different approaches to acquire all this biological information from a patient's blood could be possible to perform accurate diagnosis, estimate prognosis, and even monitor the onset of drug-resistant clones to make informed therapeutic choices and change therapy during treatment [72] .…”

Section: Extracellular Vesiclesmentioning

confidence: 99%

“…Circulating tumor DNA analysis may provide a complete genetic profile of the mutational landscape of metastatic disease, and is also correlated with patients’ relapse or changes in response to surgical or pharmacological treatment [ 73 ] . In this regard, a retrospective study of patients with primary breast cancer showed that the detection of metastatic disease, also spread in the bone, was possible by serial measurements of selected tumor-specific chromosomal rearrangements in ctDNA using droplet-based digital PCR technologies from plasma samples, with an average of almost one year before clinical recurrence detection during the follow-up of the disease, and the ctDNA amount was directly proportional to poor survival [ 74 ] .…”

Section: Liquid Biopsy In Bone Oncologymentioning

confidence: 99%

Liquid biopsies in primary and secondary bone cancers

Ucci¹,

Rucci²,

Ponzetti³

2022

Cancer Drug Resist

View full text Add to dashboard Cite

Liquid biopsies are a powerful tool to non-invasively analyze tumor phenotype and progression as well as drug resistance. In the bone oncology field, liquid biopsies would be particularly important to develop, since standard biopsies can be very painful, dangerous (e.g., when found in proximity to the spinal cord), and hard to collect. In this review, we explore the recent advances in liquid biopsies in both primary (osteosarcoma and Ewing sarcoma) and secondary bone cancers (breast, prostate, and lung cancer-induced bone metastases), presenting their current role and highlighting their unexpressed potential, as well as the barriers limiting their possible adoption, including costs, scalability, reproducibility, and isolation methods. We discuss the use of circulating tumor cells, cell-free circulating tumor DNA, and extracellular vesicles for the purpose of improving diagnosis, prognosis, evaluation of therapy resistance, and driving therapy decisions in both primary and secondary bone malignancies.

show abstract

Liquid biopsy in breast cancer: A comprehensive review

2019

View full text Add to dashboard Cite

Breast cancer is the most common cancer among women worldwide. Due to its complexity in nature, effective breast cancer treatment can encounter many challenges. Traditional methods of cancer detection such as tissue biopsy are not comprehensive enough to capture the entire genomic landscape of breast tumors. However, with the introduction of novel techniques, the application of liquid biopsy has been enhanced, enabling the improvement of various aspects of breast cancer management including early diagnosis and screening, prediction of prognosis, early detection of relapse, serial sampling and efficient longitudinal monitoring of disease progress and response to treatment. Various components of tumor cells released into the blood circulation can be analyzed in liquid biopsy sampling, some of which include circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell‐free RNA, tumor‐educated platelets and exosomes. These components can be utilized for different purposes. As an example, ctDNA can be sequenced for genetic profiling of the tumors to enhance individualized treatment and longitudinal screening. CTC plasma count analysis or ctDNA detection after curative tumor resection surgery could facilitate early detection of minimal residual disease, aiding in the initiation of adjuvant therapy to prevent recurrence. Furthermore, CTC plasma count can be assessed to determine the stage and prognosis of breast cancer. In this review, we discuss the advantages and limitations of the various components of liquid biopsy used in breast cancer diagnosis and will expand on aspects that require further focus in future research.

show abstract

Liquid Biopsy in Breast Cancer

Abstract: Lorena Incorvaia and Marta Castiglia contributed equally to this work.

Cited by 3 publications

References 35 publications

Biopsy Techniques for Musculoskeletal Tumors: Basic Principles and Specialized Techniques

Biopsy Techniques for Musculoskeletal Tumors: Basic Principles and Specialized Techniques

Liquid biopsies in primary and secondary bone cancers

Liquid biopsy in breast cancer: A comprehensive review

Contact Info

Product

Resources

About